Stability of a Cisplatin-Chondroitin Sulfate A Complex in Plasma and Kidney in Terms of Protein Binding
スポンサーリンク
概要
- 論文の詳細を見る
To assess the stability of a cisplatin(CDDP)complex prepared with chondroitin sulfate A(CSA)relative to protein binding in the circulation and kidney, a trichloroacetic acid(TCA)precipitation method was developed to measure the protein-unbound species of CDDP and the CDDP-CSA complex in plasma and kidney homogenates. The total and unbound drug concentrations were determined up to 3 h following a 2mg/kg bolus injection of CDDP or CDDP-CSA complex to rats. The stability against plasma binding was evaluated by a determination of the area under concentration-time curve from time 0 to infinite time(AUC_<(0-∞)>) ; the ratio of unbound drug (AUC_<(0-∞)>)to total drug (AUC_<(0-∞)>)was employed to estimate the availability of the unbound drug in the circulation. The results showed that a competitive reaction to platinum existed between plasma protein and the CDDP-CSA complex, but the complex accounted for more than 60% of the protein-unbound species for a dosage, compared to 30% obtained by an administration of uncomplexed CDDP. The tissue binding kinetics in kidney for CDDP and the CDDP-CSA complex was investigated by the use of homogenates. The binding rate constants of CDDP and CDDP-CSA in a kidney homogenate were 0.0040 min^<-1> and 0.0014 min^<-1> respectively. The results indicate that the CDDP-CSA complex could effectively retard the binding of CDDP to protein in the kidney. These data provide evidence that endogenous protein is able to compete for platinum from the CDDP-CSA complex, but the complex effectively retarded the protein binding reaction with CDDP in plasma and kidney as compared to native CDDP, which has the potential for reducing the accumulation of CDDP in plasma and kidney.
- 公益社団法人日本薬学会の論文
- 2001-08-01
著者
-
Ma Shen-feng
Faculty Of Pharmaceutical Science Kumamoto University
-
Ma Shen-feng
熊本大学 薬
-
Zhang Jing-shi
Faculty Of Pharmaceutical Science Kumamoto University
-
OTAGIRI MASAKI
Faculty of Pharmaceutical Science, Kumamoto University
-
SUENAGA Ayaka
Faculty of Pharmaceutical Science, Kumamoto University
-
Suenaga Ayaka
Faculty Of Pharmaceutical Science Kumamoto University
-
Otagiri Masaki
Fac. Of Pharmaceutical Sciences Sojo Univ.
-
Otagiri Masaki
Dep. Of Biopharmaceutics Graduate School Of Pharmaceutical Sciences Kumamoto Univ.
-
Otagiri Masaki
Faculty Of Pharmaceutical Science Kumamoto University
関連論文
- Enzymatic Hydrolysis of the Horn and Hoof of Cow and Buffalo
- CD36 Is Not Involved in Scavenger Receptor-Mediated Endocytic Uptake of Glycolaldehyde- and Methylglyoxal-Modified Proteins by Liver Endothelial Cells
- Effect of Olmesartan on Oxidative Stress in Hemodialysis Patients
- Oxidation and Carboxy Methyl Lysine-Modification of Albumin : Possible Involvement in the Progression of Oxidative Stress in Hemodialysis Patients
- INCLUSION COMPLEXATIONS OF FLURBIPROFEN WITH β-CYCLODEXTRIN AND TRI-O-METHYL-β-CYCLODEXTRIN
- Interaction Mode of Dicumarol and Its Derivatives with Human Serum Albumin, α_1-Acid Glycoprotein and Asialo α_1-Acid Glycoprotein
- Catalytic Properties for Naphthoquinones and Partial Primary Structure of Rabbit Heart Acetohexamide Reductase
- Carbonyl Reductase Purified from Rabbit Liver Is Not the Product of a Carbonyl Reductase Gene (RCBR5 or RCBR6) Cloned from the Rabbit Liver cDNA Library
- Characterization of Acetohexamide Reductases Purified from Rabbit Liver, Kidney, and Heart: Structural Requirements for Substrates and Inhibitors
- Purifiation and Catalytic Properties of a Novel Acetohexamide-Reducing Enzyme from Rabbit Heart
- Stereoselective Reduction of Acetohexamide in Cytosol of Rabbit Liver
- Stability of a Cisplatin-Chondroitin Sulfate A Complex in Plasma and Kidney in Terms of Protein Binding
- Sex-Dependent Pharmacokinetics and in Vitro Reductive Metabolism of Acetohexamide in Wistar-Imamichi Rats
- Individual Variation of Acetohexamide Reductase Activities in Liver Microsomes and Cytosol of Rats
- High-performance liquid chromatography with chemiluminescence detection of penbutolol and its hydroxylated metabolite in rat plasma
- Effects of Repeated Clarithromycin Administration on the Pharmacokinetic Properties of Pindolol in Rats
- Effects of α_1-Acid Glycoprotein on Erythrocyte Deformability and Membrane Stabilization(Biopharmacy)
- Characterization of Ligand Binding Sites on the α_1-Acid Glycoprotein in Humans, Bovines and Dogs
- Kinetic Studies of Covalent Binding between N-acetyl-L-cysteine and Human Serum Albumin Through a Mixed-disulfide Using an N-methylpyridinium Polymer-based Column
- EFFECT OF REPEATED ADMINISTRATION OF PYRIDINOLCARBAMATE ON THE RENAL EXCRETION OF SOME DRUGS IN RABBITS
- Characterization of a Binding Site of UCN-01,a Novel Anticancer Drug on α_1-Acid Glycoprotein
- Inclusion Complex of 3,9-Bis(N, N-dimethylcarbamoyloxy)-5H-benzofuro[3,2-c]quinoline-6-one (KCA-098) with Heptakis(2,6-di-O-methyl)-β-cyclodextrin : Interaction and Dissolution Properties
- Effect of Grinding with Hydroxypropyl Cellulose on the Dissolution and Particle Size of a Poorly Water-Soluble Drug
- Inhibitory Effects of Flavonoids on Rabbit Heart Carbonyl Reductase
- Inhibition of Rabbit Heart Carbonyl Reductase by Fatty Acids
- Purification and Catalytic Properties of a Tetrameric Carbony1 Reductase from Rabbit heart
- STUDIES ON BEFUNOLOL REDUCTASE FROM RABBIT LIVER
- In Vivo and in Vitro Binding of (-)-Hydroxyhexamide, a Major Metabolite of Acetohexamide, to Rabbit Serum
- Metabolic Reduction of Acetohexamide in Rat Kidney : Sex Difference and Effect of Streptozotocin-Induced Diabetes
- SEX DIFFERENCE OF ACETOHEXAMIDE REDUCTION IN RAT LIVER
- EFFECTS OF VARIOUS FACTORS ON METABOLIC REDUCTION OF ACETOHEXAMIDE
- REDUCTION OF ACETOHEXAMIDE BY RABBIT HEART CYTOSOL
- Effect of Phenylbutazone on Serum Protein Binding and Pharmacokinetic Behavior of Sulfadimethoxine in Rabbits, Dogs and Rats
- SPECIES DIFFERENCE IN PROTEIN BINDING DISPLACEMENT OF SULFADIMETHOXINE
- EFFECT OF PHENYLBUTAZONE ON SERUM PROTEIN BINDING OF SULFADIMETHOXINE IN DIFFERENT ANIMAL SPECIES
- MODEL ANALYSIS OF INTERFACIAL TRANSFER AND ABSORPTION BEHAVIOR OF DRUG FOLLOWING DISSOLUTION FROM COMPRESSED TABLET : IN THE CASES OF SULFONAMIDES AND β-CYCLODEXTRIN COMPLEXES
- IMPROVEMENT OF ORAL BIOAVAILABILITY OF PREDNISOLONE BY β-CYCLODEXTRIN COMPLEXATION IN HUMANS
- ENHANCED ORAL BIOAVAILABILITY OF ANTIINFRAMMATORY DRUG FLURBIPROFEN IN RABBITS BY TRI-O-METHYL-β-CYCLODEXTRIN COMPLEXATION
- IMPROVEMENTS OF SOME PHARMACEUTICAL CHARACTERISTICS OF VARIOUS STEROIDAL DRUGS BY CYCLODEXTRIN COMPLEXATION
- REDUCTION IN THE LOCAL TISSUE TOXICITY OF CHLORPROMAZINE BY β-CYCLODEXTRIN COMPLEXATION
- Study of Interaction of Pranoprofen with Human Serum Albumin : Binding Properties of Enantiomers and Metabolite
- ENANTIOSELECTIVE ORAL BIOAVAILABILITY OF O-ISOVALERYL PROPRANOLOL AS A POTENTIAL PRODRUG OF PROPRANOLOL
- Interaction of Fluorescent Probe 7-Anilino-4-methylcoumarin-3-(p)-benzoic Acid with Egg Albumin
- ENHANCED BIOAVAILABILITY OF DIGOXIN BY γ-CYCLODEXTRIN COMPLEXATION
- REDUCTION IN THE LOCAL TOXICITY OF CHLORPROMACINE AND ITS PHOTOPRODUCTS BY CYCLODEXTRIN COMPLEXATION
- PROTECTIVE MECHANISM OF β-CYCLODEXIRIN FOR THE HEMOLYSIS INDUCED WITH PHENOTHIAZINE NEUROLEPTICS IN VITRO
- CYCLODEXTRIN-INDUCED HEMOLYSIS AND SHAPE CHANGES OF HUMAN ERYTHROCYTES IN VITRO
- PROTECTIVE EFFECTS OF CYCLODEXTRINS ON THE HEMOLYSIS INDUCED WITH TRANQUILIZING PHENOTHIAZINES
- PROTECTIVE EFFECTS OF CYCLODEXTRINS ON DRUG-INDUCED HEMOLYSIS IN VITRO
- Nanomolar Quantification and Identification of Various Nitrosothiols by High Performance Liquid Chromatography Coupled with Flow Reactors of Metals and Griess Reagent
- Enhanced Dissolution of Poorly Water-Soluble Drugs by Water-Soluble Gelatin
- THE ROLE OF SERUM PROTEIN BINDING IN THE INTESTINAL ABSORPTION OF DRUGS
- Opposite Effects of Metoclopramide and Propantheline on Intestinal Absorption of Imipramine in Rats
- INTERACTION OF WARFARIN WITH HUMAN SERUM ALBUMIN
- Effect of N-B Transition on the Microenvironment Surrounding ^Cys in Human Serum Albumin
- Activity coefficients of dimethyl-.BETA.-cyclodextrin in aqueous solutions.
- The structure of the cyclodextrin complex. XI. Crystal structure of hexakis-(2,3,6-tri-o-methyl)-.ALPHA.-cyclodextrin-p-iodoaniline monohydrate.
- The structure of the cyclodextrin complex. XIV. Crystal structure of hexakis(2,3,6-tri-O-methyl)-.ALPHA.-cyclodextrin-benzaldehyde (1:1) complex.
- The structure of the cyclodextrin complex. XVIII. Crystal structure of .BETA.-cyclodextrin-benzyl alcohol (1:1) complex pentahydrate.
- The structure of the cyclodextrin complex. XV. Crystal structure of hexakis(2,3,6-tri-O-methyl)-.ALPHA.-cyclodextrin-p-nitrophenol(1:1)complex monohydrate.
- The structure of the cyclodextrin complex. XIX Crystal structures of hexakis(2,3,6-tri-O-methyl)-.ALPHA.-cyclodextrin complexes with (S)- and (R)-mandelic acid. Chiral recognition through the induced-fit conformational change of the macrocyclic ring.
- The structure of the cyclodextrin complex. X. Crystal structure of .ALPHA.-cyclodextrin-benzaldehyde (1:1) complex hexahyderate.
- The structure of the cyclodextrin complex. XVI. Crystal structure of heptakis(2,3,6-tri-O-methyl)-.BETA.-cyclodextrin-p-iodophenol(1:1) complex tetrahydrate.